secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001619856-23-000105
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q2 net loss $29.5M; CB-010 shows 94% ORR; cash runway into Q4 2025
--------------------------------------------------------------------------

- Net loss of $29.5M for Q2 2023 versus $26.7M in Q2 2022; R&D expenses $26.5M.
- Cash, equivalents, and marketable securities $292.5M at June 30, 2023; plus $134.6M from July public offering extends runway into Q4 2025.
- CB-010 ANTLER trial: 94% ORR (15/16) and 69% CR (11/16) in dose escalation; enrolling second-line LBCL expansion.
- Pfizer invested $25M in common stock on June 30, 2023; proceeds to advance CB-011.
- Plan to share FDA feedback on CB-010 pivotal trial by YE 2023; initial dose expansion data in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000105/0001619856-23-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000105/crbu-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer